AbCellera Biologics launched an underwritten public offering aimed at raising $200 million through a mix of common shares and pre-funded warrants. The financing is designed to fund continued clinical development of its menopause antibody ABCL365 and, centrally, its lead program ABCL635. The company said net proceeds will support ABCL635’s progression through clinical trials as well as working capital and general corporate purposes. Jefferies, J.P. Morgan, Cantor, UBS Investment Bank, and BMO Capital Markets are listed as joint book-running managers. AbCellera emphasized that completion of the offering is subject to market and other conditions, leaving timing and final structure dependent on investor appetite. Still, the deal highlights how clinical-stage biotechs with late-stage or pivotal-adjacent priorities are leaning on capital markets to extend runway and maintain trial pace. For ABCL635, the offering is a direct signal that AbCellera intends to keep resources aligned to its clinical milestone cadence, while ABCL365 continues progress in non-hormonal control of moderate-to-severe vasomotor symptoms via NK3R targeting.